Nathan L. Mata
much, very you Yes. Thank Tom.
a subjects. disease, This X-year to from our study, open-label there of is mutations in I lot are with Australia. over mentioned, X,XXX a the X-year be from them you don't Taiwan Phase known subjects are adolescent data disease associated was, share of people II Stargardt about all So not study and understand enrolled with pathogenic. to what What known XX the Stargardt I'd as like is study
benign. In to fact, many mild are
So one was Dr. L. we in analysis University. the of the He disease initially the gave And the genetic to we to actually determine geneticists in cohort. one Stargardt evaluated of Columbia at Allikmets our in did Rando composition genetic the testing cohort mutations, preeminent vitro those these data world, there our X pathogenic genetic where pathogenicity. that these which that of predict showed were our allele in subjects alleles. determined data biolytic X, would XX And in subjects, and XX was had in actually in severe moderate a premier
our cohort disease the to predicted severe through progress very mutations pathogenic has course. rapidly really entire So that were
An of a particular independent genetic Depletion is Combined It the that severity by every genetic CADD for to our called single one genetic severity the scores and subjects X% provided of something stands most had and mutation. of score. are you assessment of exception the score subjects the XX. Scores X or these degree the CADD tells Annotation-Dependent above of XX with above deleterious X variant be predicted among
severity cohort X And these atrophic of lesions. the we of XX% we kids. genotypes, never the So have represents despite X independent confirmations that which of of severity the of subjects, had the genotypes these developed
have occurred. Over conversion the atrophic is these lesion. have form analysts of as disease, autofluorescent in lesions XX% with an lesions subjects, that's and at. autofluorescent see that and of these known decreased And of convert one time, in in This we're to type early looking we autofluorescent. here should parameters only that questionably never a they where study, lesion, is So subjects a I mentioned this came which of
same -- pairs mutations. data that approach had from course. outcome there a interesting an identical for that we their using the are therapeutic mutations of found siblings predict that Another exact the are because disease was competing X ours is of This important genetic companies premise identical as identical companies
and whether premise evaluate opportunity So or that not to validity to any determine this gives there's us it. an
one open we're of this see to look essentially Because an we well-being want acuity. to at visual effect metrics study, the is having patients, improve to is label
And to look XX year a significant duration subjects called that subjects, mean in study. subjects that the predicts BCVA a enrollment. acuity enrollment. found X prior clinically looked sub-X natural cohort these are subjects within of basically years we bilateral losing that's liters The for in we letters would in we to our per So be was eyes, the larger our loss. losing both during And at prior in specifically visual history of over study, vision loss there who
to eye we to So an see subjects these keep that on fare. how want
have vision have which you compromised, non-atrophic case. is they're there data these are kids fact some lesions, they being sort are all that these the their be means significantly, current all lesions atrophic the vision starts be the actual these wheel scientific visual But is QDAF and lesions, Another don't That's the full kids losing on important actually some lesions lesions, of have community over not can vision, to thing they about compromised suggests pre-enrollment that acuity. very because these data, and losing involved seems and function, will of time. atrophic to before that compromise these them of important, have that thinking of in visual effect
can different comparisons, the this sibling fact, and did the levels this identical BCVA of data found find regarding presentation. appendix loss, be do, we finally, sibling of with that subjects And in have mutations in
significantly, That If in letters X-year if coming the that's we that's significant overview left-hand about subjects subjects vision those those on year. mean look is not This with all shown But shown because side, is the study of we're we per subjects. XX the really the see before we look the year essentially at X.X all losing per that stabilization. vision right-hand visual a subjects acuity letters into side. loss, changing over prior shows that in that at on of is study, loss
per they're year. only X.X letters losing Now about
So acuity growth. the progression if do is effect in reason kids, visual lesion you these you're stabilized and having That's could And on the that we've it. we've significant. altered only some really, very significantly
to So I to right want go that now.
images types an And sizes. look never subject baseline. representations all basically in lesion, you subjects subjects these of over these But subjects have different upper that grew right-hand to these I want what XX the The side of measuring at atrophic all atrophic lesions what autofluorescent see on X are just how anatomically like. mentioned, of like. you XX converts This but are we're this is I sort looks of to they're fovea, lesion that time As show the here encroaching autofluorescent lesion.
the autofluorescent atrophic In matched And as very these atopic grew in the the single of increase by every And something the I found X of are XX every we that said was case, except in X, was decrease lesions. a actually area interesting. what subject. there area before,
and autofluorescent lesion an bar, is see autofluorescence. part, is The the the atrophy you growing orange an perimeter boundary, that's lesion not of blue wherever where a within you the that's So the of growing. is of a actually see significant the atrophy decrease increase Only because that's the reason size.
So potentially grow. out because it suggests that to over no the else itself place time, this could lesion burn there's for lesion
to there So on that outside certainly anymore. these are would lesion preserving but our to with cells are we are cannot telling They're growing further sort the cells die the us treatment, data them margin predestined save that of of lead what we're growth. not perhaps
subject one of we a just So a one important outside where was subject. area lesion There only as found QDAF was initially this pretty of that lesion, so is finding.
lesion XX these there's if the it essentially XX if growth. XX, and XX genotypes, the growth all back But that at have -- they the both to lesions finally, have versus And X, then have absolutely they very getting somewhat no genetic XX look look duration. and at similar XX disease and same and X and identical in subject you XX, identical subjects X subjects had have and mutations. Yet the but kids yes, different you was mutations,
lesion So growth an data, a identify just not metric, these predict course. on identical mutations, disease again, do
of are other how that an one assessment We is of actually graded. lesions have piece pass information along, to and important very these
routine camera currently, of area. that then and is takes perimeter that the an that the a the lesion a lesion. boundary then draws computer So so physical we're goes in you reader autofluorescent that And tell everyone can methodology the using. basically reader, picture It's around the the of using a
an being single lesion because X every grade of those to agree breaker. validated. image, can move the has sort be terms have with to on into third readers And size in a be before there to it in has readers and agreement tie variants, come don't X a So if reader certain of basically
It all looking over, the it's subject any and one specific an method very red, So doesn't in look at bias. this it's particular is interim-reader to time-consuming. area
developed let's a assessing has shortcomings AI-based lesions. So of to the which use gray of is area of mathematical in the to here disk. is these This in methodology, disease the level sort method the size used order be for our new a the center address currently basically in that would of this healthy density represented reading say, classification density lesions nerve the of tissue, by optic of out tissue, area
doing predict lesions. either autofluorescence gradation levels, for it's a looking grading we're lesions. atrophic macula it's in case, gray different the areas or the atrophic and this scan would So at In of looking of at just that
within that traditional So of reading the And baseline, our of had XX rescan use removes methodology they center the macular found that the pick something lesions eyes our When to this is subjects at it not out is potential methodology reader this atrophic bias because important up. at that baseline. images did of and equation. the X subject
asked was these what's see in they to with subjects these we our the macular happening developed. growth and it data So identified all reading back go to in. is reread This images that center lesion that
XX, left-hand side until lesions over the encroachment and the linear there's shows completely no which months. time. area growth stops macula On of month time It's the it into XX lesion at into the during macular the further pretty the you about subsequent
XXX% where entire we're with showing than of single the here, looking to our the And the macula the mean data, over X-millimeter into you subjects, same basically exact side more the occupied percent involvement except in is On is digit change -- about would macula at the lesion macula. into zone can they never of see lesion. the time, left-hand get
again, a our because into data because significant, a we're and we're renders now macula, halting So acuity this getting we vision lesion significant visual observation. why is sensible, understand stabilization of growth very the it
is whatsoever X-year is a And University. the the their the testament safety years it in residues in Columbia pocket Finally, X this safety start data. that over terms way that kids. binding of orientation. this observation, biology the these by This there systemic targets specificity by AE data. want I retinol the drug-related X. this of X-dimensional this in saying drug, to was protein in drug hasn't the else exist to And been of at X binding these are residues just Basically, nowhere designed scientists the of
So and systemically this specific very the drug was AE supposed is that to basically tell be us very clean. it data
drug-related are to these we're because in thing likes, having that by they're differences see other AEs biological to manageable is What retina. AEs are in by the accommodating telling ocular we of the terms events us want we're completely light. the seeing AEs because important they're intended effect And about these driven anticipated and
confers eye, of form vision. light chromatopsia xanthopsia. The by This color called which is your cone first is and mediated a in photoreceptor bright a
these from A light regimen, dark our suddenly it wake transition cone But a supplying environment, photoreceptors want under patients when we're immediately. treatment sort to of up. slowly. bright They a So only vitamin
there'll period xanthopsia. fire have So left visual AE. this transit of of that's the photoreceptors field. and yellow, are reporting all is which maximal produce in But course, of a use kids because these mild one time be cone of of this In no in electrically will study the has miss A, don't they and color case, vitamin amount
is dark This opposite Finally, delayed manifestation. the one is other the adaptation.
a to to So a of a disease AE there bright to particular is environment, you this very process. dim when transition in is light. the be actually from manifestation darken the ability needed This environment accommodate delay will a
So disease delayed have patients with already adaptations. Stargardt dark
And of left this. are reporting as one's that's entity they're why it. pharmacological accommodating this study transient. or probably of So again, used most them mediated mild no because And
has I And say over vice transitions Phase is for can dark be as rate our this can very helpful to III our been the of study I versa. from said, that And X%. AEs bright from these very, importantly, these and in mitigated X AEs year than kids. by dropout dosing in less moderating
significant. is that So
the which the Night vision minutes a exacerbation delayed dark of more the impairment The is a error chromatopsia. score of manifestation more. increasing or on XX FMXXX the severe more severe delay is is adaptation,
headache, You acuity, we that occur their see X subject. in use they're AEs. the intermittent can And visual these think, to trained while the subjects when experiencing
of that Stargardt the essentially overview the now and Tom the over to geography. I'll studies studies. the move you the I that, the So with overview of showing those here II We're identical. in discussed, These trials trials. DRAGON DRAGON are There's differences
Sakigake principally X:X has study are Tom DRAGON involved Both As again, the and patients. DRAGON the essentially, for DRAGON randomization doing done the a except a Japan X:X in mentioned, are we is blind. There the randomization demographics difference similar II, II the randomization. vis-a-vis double in have because in that. the study We're a designation studies fewer
safety assessment, every these the inclusion subjects. other key efficacy, is the that, for et is criteria than as same other But cetera,
these is in we Phase quite similarity because safety or in promising efficacy and studies we trending optimism studies. the have DRAGON II study II study both we match Phase the have the X you DRAGON believe of II very because data I that So well, and and how and
III Moving trial indication, forward reflect Stargardt very in Phase higher and studies similar course, to the the the of essentially the as the the show atrophy the is design in these GA of of disease to difference population. identical. you trial geographic disease subjects well number Otherwise, to in only geographic the prevalence in are The atrophy higher to very, is trials. GA, design it
whatever what Stargardt see high be we Stargardt, highly the that setting and between disease we studies the patients enrolled. we So again, similarity particular And same is in And have lagging the for it in principal reason see very in of pathological geographic GA are we behind predictive expect there's GA. atrophy disease, dose. could because the the starters a
financial So for it results. with the back turn that, over to Chuang Hao-Yuan I'll
